Guangzhou Recomgen Biotech Co., Ltd.   Report issue

For profit Phase 4
Founded: Guangzhou China (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2016
NCT02835534
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Guangzhou Recomgen Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (2)

alteplase (Activase) (2 trials)

tenecteplase (tnkase) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 4)

Ischemia (Phase 2)

Myocardial Infarction (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 2